| Date Filed | Type | Description |
| 05/03/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 04/26/2019 |
SC 13D/A
| BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in OncoMed Pharmaceuticals, Inc. |
| 04/24/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/24/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/24/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/24/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/24/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/24/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/23/2019 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 04/23/2019 |
4
| Hager Alicia J. (SVP and General Counsel) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Unknown transaction of 39,488 shares
@ $0 |
|
| 04/23/2019 |
4
| ROOT JONATHAN D (Director) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Unknown transaction of 121,020 shares
@ $0 |
|
| 04/23/2019 |
4
| LASERSOHN JACK W (Director) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Unknown transaction of 185,709 shares
@ $0
Unknown transaction of 1,119,905 shares
@ $0
Unknown transaction of 380,299 shares
@ $0 |
|
| 04/23/2019 |
4
| Lewicki John A. (President and CEO) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Unknown transaction of 142,534 shares
@ $0 |
|
| 04/23/2019 |
4
| PAKIANATHAN DEEPIKA (Director) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Unknown transaction of 1,991,602 shares
@ $0
Unknown transaction of 18,940 shares
@ $0 |
|
| 04/23/2019 |
4
| Li Yvonne (See Remarks) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Unknown transaction of 65,895 shares
@ $0 |
|
| 04/23/2019 |
4
| Stagg Robert (See Remarks) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Unknown transaction of 28,917 shares
@ $0 |
|
| 04/23/2019 |
4
| KARSEN PERRY A (Director) has filed a Form 4 on OncoMed Pharmaceuticals Inc|
Txns:
| Unknown transaction of 80,500 shares
@ $0 |
|
| 04/23/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/23/2019 |
GN
| Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc. |
| 04/19/2019 |
GN
| Report: Exploring Fundamental Drivers Behind Murphy Oil, Clean Harbors, OncoMed Pharmaceuticals, RiceBran Technologies, Zedge, and Aptose Biosciences — New Horizons, Emerging Trends, and Upcoming Developments |
| 04/18/2019 |
GN
| Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting |
| 04/17/2019 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events |
| 04/17/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/20/2019 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 03/15/2019 |
SC 13D
| BIOTECHNOLOGY VALUE FUND L P reports a 10.4% stake in OncoMed Pharmaceuticals, Inc. |
| 03/15/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/15/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"FORM 8-K",
"Contingent Value Rights Agreement, by and between OncoMed Pharmaceuticals, Inc. and Computershare Inc., as rights agent",
"Form of Stockholder Support Agreement",
"OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights REDWOOD CITY, Calif., March 15, 2019 — OncoMed Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declared a one-time special dividend in the form of a contractual right to receive, on a pro rata basis, cash payments from OncoMed upon the actual receipt by OncoMed or its affiliates of certain contingent cash amounts in the future following the exercise by Celgene Corporation or certain of Celgene Corporation's affiliates of the exclusive option granted by OncoMed to Celgene in relation to OncoMed's etigilimab product. More specifically, if a specified approval or sales milestone is achi..." |
|
| 03/15/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/15/2019 |
GN
| OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights |
| 03/12/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/07/2019 |
10-K
| Annual Report for the period ended December 31, 2018 |
| 03/07/2019 |
8-K
| Quarterly results |
| 02/22/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/15/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
|